C
hildren's Cancer Group (CCG) study 2891 was a phase 3 clinical trial for children and adolescents younger than 21 who had newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). One of the major objectives of the study was to evaluate the effect of intensively timed induction therapy compared with a standard timing regimen (1) . Patients who entered remission were randomized further to allogeneic bone marrow transplantation (BMT), autologous BMT, or chemotherapy (2) . Three years into the study and before the reporting of studies of granulocyte colony-stimulating factor (G-CSF) in adults with AML, the CCG-2891 study committee decided to add G-CSF to the intensively timed induction regimen. The committee hypothesized that the addition of G-CSF would reduce the length of neutropenia and deaths from infection and toxicity. Patients with acute promyelocytic leukemia (APL, FAB M3) were excluded from further study entry because of the theoretical concern, when the Intergroup APL Study opened in April 1992 (3) , that G-CSF would stimulate acute promyelocytic leukemic blast proliferation. Within months, the standard timing regimen was closed because of inferior event-free survival (EFS) and subsequently confirmed inferior overall survival (OS). This report compares toxicities and indicators of outcome for the intensively timed induction regimen with G-CSF (Int-plus-G) and without G-CSF (Int-minus-G).
To our knowledge, CCG-2891 represents the first large, prospective study of the use of G-CSF in induction therapy for children with AML. The report focuses specifically on measures of absolute neutrophil count (ANC) and platelet count, time to count recovery, hematologic and nonhematologic toxicity, infections, overall induction outcome, OS, EFS, and early response as measured by day 7 bone marrow.
PATIENTS AND METHODS
Children's Cancer Group study 2891 opened in October 1989 and closed in April 1995. Of 1114 children registered, 1098 were deemed to be eligible after central review (18 were ineligible because they had diagnoses other than AML or MDS). A homogeneous subset of patients with de novoAML as a secondary malignancy. Patients on the standard timing arm (n ‫ס‬ 335) and patients randomized to the standard timing arm who received intensive timing after the standard timing arm closed (n ‫ס‬ 13) were not considered in this analysis. From this subset, patients with acute promyelocytic leukemia (FAB M3, n ‫ס‬ 27) also were excluded because of unbalanced representation in the groups of patients who did and did not receive G-CSF. We herein present data on 258 patients who did not receive G-CSF and 254 patients who did receive G-CSF.
Induction Therapy
The induction regimen consisted of two courses of the two-cycle DCTER regimen (1), a five-drug combination of dexamethasone, cytarabine, 6-thioguanine, etoposide, and daunorubicin administered over 4 days. Intensive-timing patients received a second cycle of DCTER after a 6-day rest, irrespective of bone marrow or hematologic status. Delays of 2 to 4 days were permitted for patients who experienced severe ileus or other life-threatening events with the first cycle of therapy. Bone marrow biopsies and aspirates and peripheral blood counts were obtained on days 7 and 14 of course 1 and at the end of course 1, with additional studies performed as clinically indicated. Patients showing no leukemia response (i.e., >40% blasts in a mildly hypocellular to hypercellular marrow) at the end of course 1 were considered protocol failures. These patients discontinued protocol treatment, but their follow-up continued. Patients who responded but whose bone marrow remained hypocellular with pancytopenia resumed treatment when their ANC was at least 1,000/L and their platelet count was at least 100,000/L, with less than 5% blasts in recovering bone marrow. Patients then received their second two cycles of therapy without dose modification. Marrow and peripheral blood count status were determined at the end of the second course of therapy. Patients exhibiting residual leukemia were removed from protocol therapy, whereas patients in remission (i.e., ANC Ն 1000/L, platelet count Ն100,000/L, with <5% marrow blasts) proceeded to the postremission phase.
Patients on the Int-plus-G arm received filgrastim (G-CSF) beginning on day 6 of each course at a dose of 5 g/kg administered subcutaneously or intravenously over 30 minutes each day until ANC was greater than 1,500/L. Thus, in course 1, the administration of G-CSF began 2 days after completion of the first cycle of DCTER (days 0-3) and continued through the second cycle of DCTER (days 10-13) until neutrophil recovery. The same pattern was repeated for course 2. The use of G-CSF was discouraged otherwise, including use during the postremission phase.
Postremission Phase
Patients in remission after four cycles of induction therapy were eligible to proceed to the postremission phase of this study, which has been described in detail elsewhere (1,2). In brief, patients with compatible matched-related donors were allocated to receive allogeneic BMT. Patients without matched-related donors were randomized to receive either nonmyeloablative chemotherapy or autologous BMT.
Statistical Considerations
Analyses compared patients assigned to the Int-minus-G arm of CCG-2891 with patients assigned to the Int-plus-G arm using an "intent-to-treat" analysis of data obtained through July 31, 2001 . The significance of observed differences in proportions was tested using the chi-square test and Fisher exact test when data were sparse. For continuous data, the Mann-Whitney test was used to compare the medians of skewed distributions (4) .
Although the protocol recommended bone marrow studies on days 7 and 14 of course 1, the actual measurements were obtained on a range of days. To allow valid comparisons of day 7 bone marrow measurements, only marrow studies on days 5 to 9 were included for day 7 comparisons. The actual day 14 marrow measurements were performed on such a variable range of days that valid comparisons were not feasible.
The time to ANC recovery was calculated as the number of days from the start of induction therapy to the first date ANC reached 1,000/L after day 6 of therapy. Patients were right censored for recovery at the time of last reported ANC if their induction therapy was terminated for any reason. The time to recovery of platelets to 100,000/L and the time to hematologic recovery (i.e., both ANC and platelet recovery) were calculated in a similar manner.
Recovery survival curves were calculated using the method of Kaplan and Meier, and median time to recovery was obtained from these curves (5) . Differences in the times to recovery for the patients not receiving and receiving G-CSF were tested using the log-rank (6) and WilcoxonBreslow (7) tests for noncrossing and crossing survival curves, respectively.
The Kaplan-Meier method was used to calculate estimates of OS from study enrollment and from achieving remission after two courses of induction therapy; EFS, defined as the time from study enrollment to induction failure, marrow relapse, or death; and disease-free survival (DFS), defined as the time from remission induction at the end of course 2 to marrow relapse or death. Patients lost to followup were censored at their last known points of study, with a cutoff of January 31, 2001 . Confidence intervals were calculated using Greenwood's formula (8) . Differences in OS, EFS, and DFS were tested for significance using the logrank statistic.
RESULTS
Two hundred fifty-eight patients received induction therapy without G-CSF and 254 patients received induction therapy with G-CSF. The two arms (Int-plus-G vs. Intminus-G) were not different with regard to several demographic characteristics: median age (7.7 years vs. 7.5 years, P ‫ס‬ 0.970), gender (P ‫ס‬ 0.094), and race (P ‫ס‬ 0.625). The Int-plus-G and Int-minus-G arms were also similar with respect to several characteristics at diagnosis: median white blood cell count (20,600 vs. 23,700/L, P ‫ס‬ 0.639), median platelet count (56,000 vs. 59,500/L, P ‫ס‬ 0.860), FAB classification (P ‫ס‬ 0.326), and cytogenetics (P ‫ס‬ 0.351). Table 1 summarizes ANC and platelet counts during induction for the two groups. Measurements of ANC were reported a median of four times (range 1-9) during induction; platelet counts were reported a median of four times (range 1-7). The two groups had a similar median ANC at day 7 (93 for Int-plus-G, 82.5 for Int-minus-G, P ‫ס‬ 0.655). Patients receiving G-CSF had a significantly higher median ANC at the end of course 1 (3,391.5 vs. 1,659, P < 0.0001) and at the end of course 2 (2,482 vs. 1,815, P < 0.0001). Conversely, the median platelet count for the patients receiving G-CSF was lower at day 7 (37 vs. 44, P ‫ס‬ 0.015) and at the end of course 1 (171 vs. 228.5, P ‫ס‬ 0.004), with nonsignificantly lower counts at the end of course two (169 vs. 184, P ‫ס‬ 0.396).
Absolute neutrophil and Platelet Counts

Count Recovery
The time from start of induction therapy to ANC recovery to at least 1,000/L in course 1 was significantly shorter for the patients receiving G-CSF (P ‫ס‬ 0.003, Fig. 1 ). The median time to ANC recovery in course 1 was 38 days for the patients receiving G-CSF and 42 days for those not receiving G-CSF. The rate of ANC recovery in course 2 also was shorter for the patients receiving G-CSF (P < 0.0001), with a difference in median time to recovery of 7 days (44 vs. 51 days).
The time to platelet recovery to at least 100,000/L was similar for the two arms in course 1 (P ‫ס‬ 0.607) and course 2 (P ‫ס‬ 0.175) of induction therapy. The median time to platelet recovery was 40 and 42 days during course 1 and 45 and 48 days during course 2 for the patients receiving G-CSF and those not receiving G-CSF, respectively.
The time from the start of induction to hematologic recovery (i.e., ANC and platelet recovery) in course 1 was significantly shorter for the patients receiving G-CSF (P ‫ס‬ 0.001, Fig. 2 ). The time to hematologic recovery in course 2 was also shorter for the patients receiving G-CSF arm (P < 0.001), with a 10-day shorter median time to recovery (45 vs. 55 days).
Induction Length
The number of days required to complete the first course, second course, and both courses of induction therapy is summarized in Table 1 . The length of induction was a median of 2, 7, and 9 days shorter for the patients receiving G-CSF than for those not receiving G-CSF in course 1 (P ‫ס‬ 0.051), course 2 (P ‫ס‬ 0.005), and overall induction (P ‫ס‬ 0.001), respectively. 
Hospital Stay
The hospital stay of a patient during induction therapy was left to the discretion of the treating physician. Length of stay was a median of 3, 2.5, and 6 days shorter for the patients receiving G-CSF than for the patients not receiving G-CSF in course 1 (P ‫ס‬ 0.003), course 2 (P ‫ס‬ 0.008), and overall induction (P ‫ס‬ 0.0004), respectively (see Table 1 ).
Toxicity and Infections
A similar proportion of patients receiving and not receiving G-CSF experienced one or more grade 3 or 4 nonhematologic toxicities, using National Cancer Institute criteria (55% vs. 54%, P ‫ס‬ 0.846). A similar percentage of patients receiving and not receiving G-CSF experienced grade 3 or 4 hemorrhages (1% vs. 1%, P ‫ס‬ 0.684). Severe hyperbilirubinemia was the only specific toxicity for which the rates of occurrence differed for the two arms, with patients receiving G-CSF more likely to experience severe hyperbilirubinemia (11% vs. 6%, P ‫ס‬ 0.024).
Patients receiving and not receiving G-CSF had similar percentages of one or more proven infections (83% vs. 80%, P ‫ס‬ 0.295), fatal infections (3.5% vs. 5.8%, P ‫ס‬ 0.224), and bacteremias (39% vs. 39%, P ‫ס‬ 0.887).
Induction Outcome
Outcomes after two courses of induction therapy for the two groups of patients are summarized in Table 2 . Patients who withdrew from the study without knowledge of remission status (n ‫ס‬ 18) were excluded from the analysis. Patients receiving and not receiving G-CSF had similar remission rates (82.4% vs. 77.5%, P ‫ס‬ 0.170), induction failure rates (10.0% vs. 13.1%, P ‫ס‬ 0.279), and induction death rates (7.6% vs. 9.4%, P ‫ס‬ 0.467).
Comparison of Survival Rates
Comparisons of OS, EFS, and DFS for the two groups of patients (Fig. 3) are summarized in Table 3 , along with actuarial estimates at 6 years and corresponding 95% con-
FIG. 2.
Time (in days) from start of induction therapy to absolute neutrophil count and platelet recovery in course 1 for patients who were not receiving granulocyte colonystimulating factor (G-CSF) and those who were receiving G-CSF (P = 0.001).
FIG. 1.
Time (in days) from start of induction therapy to absolute neutrophil count recovery in course 1 for patients who were not receiving granulocyte colony-stimulating factor (G-CSF) and those who were receiving G-CSF (P = 0.003).
fidence intervals. No significant differences were observed in OS from on-study (49% vs. 49%, P ‫ס‬ 0.973), EFS from on-study (44% vs. 43%, P ‫ס‬ 0.668), DFS from achieving remission (54% vs. 57%, P ‫ס‬ 0.562), or survival from achieving remission (58% vs. 63%, P ‫ס‬ 0.332) between the patients receiving and not receiving G-CSF. Within each of the three postremission treatment arms (allogeneic BMT, autologous BMT, and chemotherapy), both groups had similar DFS and survival experiences (results not presented).
Marrow Cellularity
Bone marrows were classified by treating physicians as hypercellular, normocellular, or slightly, moderately, or markedly hypocellular. To investigate whether the effect of G-CSF on OS and EFS differed according to day 7 bone marrow status, we dichotomized bone marrows as being hypocellular or at least normocellular. For ease of discussion, these categories will be referred to as "hypocellular" and "hypercellular," respectively.
Patients with hypercellular day 7 bone marrows and patients with hypocellular day 7 bone marrows were not different with regard to several on-study and demographic characteristics (results not presented). Patients with day 7 bone marrows that were hypercellular had a significantly lower induction remission rate (68% vs. 83%, P ‫ס‬ 0.003), OS (42% vs. 53%, P ‫ס‬ 0.029), and EFS (36% vs. 46%, P ‫ס‬ 0.023) than patients with hypocellular bone marrows ( Table 4 , Fig. 4 ).
Further categorization of the patients based on bone marrow cellularity and treatment group identified 46 patients receiving G-CSF with hypercellular marrow, 34 patients not receiving G-CSF with hypercellular marrow, 158 patients receiving G-CSF with hypocellular marrow, and 174 patients not receiving G-CSF with hypocellular marrow. The distribution of hypercellular and hypocellular day 7 bone marrows did not differ for the two arms of the study (P ‫ס‬ 0.11).
Induction remission rates, OS, and EFS for the four cellularity/G-CSF groups are provided in Table 4 . Patients who did not receive G-CSF and who had a hypercellular marrow had a 53% remission rate, which is significantly lower than the 78% observed for the patients with a hypercellular marrow who received G-CSF (P ‫ס‬ 0.023), the 83% for patients with a hypocellular marrow who received G-CSF (P < 0.001), and the 82% for patients with a hypocellular marrow who did not receive G-CSF (P < 0.001). Patients with a hypercellular marrow who did not receive G-CSF also had inferior OS and EFS relative to the patients with a hypocellular marrow who received G-CSF and the patients with a hypocellular marrow who did not receive G-CSF. Although the patients with a hypercellular marrow who did not receive G-CSF had nonsignificantly lower OS (P ‫ס‬ 0.153) and marginally significantly lower EFS (P ‫ס‬   FIG. 3 . Survival from enrollment (A) and event-free survival (B) for patients who were not receiving granulocyte colony-stimulating factor (G-CSF) and those who were receiving G-CSF. Int − G, patients not receiving granulocyte colony-stimulating factor; Int + G, patients receiving granulocyte colony-stimulating factor.
95% confidence intervals are given in parentheses.
0.053) than patients with a hypercellular marrow who did receive G-CSF, estimates of OS and EFS at 6 years for the patients with a hypercellular marrow who did not receive G-CSF (35 ± 15% and 26 ± 15%, respectively) were 13% and 17% lower than for patients with hypercellular marrow who did received G-CSF (48 ± 13% and 43 ± 14%, respectively; see Table 4 and Fig. 4) .
DISCUSSION
In the CCG-2891 study, G-CSF was added to the intensively timed DCTER regimen in a post facto attempt to moderate a very toxic but effective AML induction therapy. The conclusions of these analyses are therefore limited by the consecutive rather than randomized nature of the two Hyper −G, hypercellular not receiving granulocyte colony-stimulating factor (G-CSF); Hyper +G, hypercellular receiving G-CSF; Hypo-G, hypocellular not receiving G-CSF; Hypo +G, hypocellular receiving G-CSF. 95% confidence intervals are given in parentheses.
treatment arms being compared. Nonetheless, the two arms were balanced with regard to patient demographics and disease characteristics at diagnosis. Further, no effect of time at study entry on outcome (i.e., a learning curve effect) was observed. Therefore, the conclusions drawn appear valid and are in keeping with the observations made by other investigators in adults with AML (9-13) .
In vitro, G-CSF has been shown to support the growth of neutrophil colonies, enhance neutrophil effector function, and increase neutrophil count (14, 15) . In CCG-2891, the use of G-CSF shortened the time to neutropenic recovery in courses 1 and 2 of induction by a median of 4 and 7 days, respectively. A reduced duration of neutropenia due to G-CSF also has been observed in studies of adults with AML (9-13), in patients with MDS (16) , in studies of children and adults with acute lymphoblastic leukemia (17) (18) (19) (20) (21) (22) (23) , after BMT (24) (25) (26) (27) , after chemotherapy for solid tumors (28) (29) (30) (31) (32) , and in studies of other clinical conditions (33) (34) (35) (36) .
Although G-CSF resulted in higher median neutrophil counts at the end of the first and second courses of induction therapy in the current study, G-CSF also resulted in lower median platelet counts at similar time points. A possible explanation is that earlier hematopoietic progenitors were redirected to neutrophil production, away from other lineages.
Patients who received G-CSF on CCG-2891 spent significantly less time in the hospital than patients who did not receive G-CSF. Because children with AML who have neutropenia are at high risk for death and complications, inpatient treatment is necessary for the management of these patients. Thus, the shorter hospital stay required during induction noted for the G-CSF patients was most likely a direct result of the reduced length of neutropenia in these patients. Differences in the incidence of severe toxic events, infections, and fatal infections were not observed. Interestingly, only one study of adults with AML has reported a significant reduction in hospital stay due to G-CSF (12) . None of the adult AML studies have shown a decrease in the incidence of infection due to G-CSF (10-13).
In our study, patients receiving G-CSF during intensively timed induction therapy had a nonsignificantly different induction remission rate (82.4% vs. 77.5%, P ‫ס‬ 0.170) and similar survival experiences to patients not receiving G-CSF. However, the study was not powered to make such comparisons. Studies of adults with AML (9-13) also have not observed a beneficial effect of G-CSF on survival or remission rate. However, one study did observe a trend for an increased remission rate for patients receiving G-CSF (10) . Results are similar, although the timing of G-CSF varied. Similar to our study, some studies administered G-CSF concomitant with induction therapy; others administered it after induction therapy was completed.
Day 7 bone marrow was an important predictor of longterm response in CCG-2891. The subgroup of CCG-2891 patients with hypercellular day 7 marrow who received G-CSF had remission rates and EFS superior to that of similar patients who did not receive G-CSF. In one adult AML trial, G-CSF was reported to improve the remission rate, primarily in the subgroup of patients with residual marrow blasts on day 8 (11). This observation is clearly similar to the observation made for the subgroup of patients with a hypercellular marrow who received G-CSF in this report. In another adult AML trial, G-CSF was restricted to patients with hypocellular bone marrows at day 10 of induction (13) . The mechanism of selective benefit for patients with a hypercellular marrow who received G-CSF is not clear. Possible explanations may include the differentiation of leukemic blasts by G-CSF and/or the cell cycle synchronizing and "driving" of leukemic stem cells by G-CSF (37), thereby increasing the efficacy of chemotherapy. We cannot exclude the possibility that G-CSF affected normal neutrophils such that the day 7 bone marrow artificially appeared to be more cellular. However, we believe this is unlikely, because G-CSF was not administered until day 6 of induction.
In our study of children with AML and in studies of adults with AML, G-CSF decreased the duration of neutropenia, did not substantially reduce infectious complications, and did not have an effect on survival or EFS. Similar qualitative results have been obtained in studies of granulocyte-macrophage colony-stimulating factors (GM-CSF) in adults with AML (38) (39) (40) (41) . Perhaps it is not surprising that G-CSF has raised the neutrophil count consistently but has had only a modest effect on toxicity and infectious complications and no effect on survival. The most important factor contributing to the success of AML induction remains the effectiveness of the induction therapy. Fortunately, G-CSF does not appear to affect the antileukemia efficacy of current therapy or stimulate leukemia cells to divide in vivo. A modest increase in the neutrophil count may not reach clinical significance in decreasing the rates of death and complications without a concurrent increase in the remission rate.
In summary, the results of this study suggest that G-CSF administered during intensively timed induction therapy for children with AML can decrease the time to neutropenic recovery, the length of induction therapy, and the length of hospital stay without adversely affecting toxicity and longterm outcome.
